Strides gets USFDA nod for generic anti-anxiety tablets

Drug firm Strides Arcolab today received approval from the US health regulator for its generic Buspirone Hydrochloride tablets used for treating anxiety disorders.

The company has received approval from the United States Food & Drug Administration (USFDA) for Buspirone Hydrochloride tablets USP in the strengths of 5 mg, 10 mg, 15 mg and 30 mg, Strides Arcolab said in a statement.

According to IMS data, as on September 2013, the US market for generic Buspirone tablets was nearly $65 million, it added.

"The product will be manufactured at the company's oral dosage facility at Bangalore and marketed directly by Strides in the US Market," the company said.

Buspirone tablets are used for the treatment of anxiety disorders and the short-term relief of the symptoms of anxiety, it added.

Strides Arcolab has 5 manufacturing facilities and has presence in more than 75 countries.

The company's scrip closed at Rs 657.05, down 1.93%, on the BSE.